Evidence map›Paper›PMID 42871514›Full record

ArticleJournal of clinical practice and research2026

FOXM1 Drives Subtype-Specific Dysregulation of Prognostic miRNAs in Breast Cancer Cells.

Zuhal Hamurcu, Venhar Cınar, Ayse Doga Karipcin, Ahsen Güler, Zeynep Yılmaz Sükranlı, Mehmet Memis, Elif Funda Sener, Serpil Taheri, Bulent Ozpolat

Abstract read
In one paragraph

Article in Journal of clinical practice and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zuhal HamurcuDepartment of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Venhar CınarDepartment of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Ayse Doga KaripcinDepartment of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Ahsen GülerDepartment of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Zeynep Yılmaz SükranlıDepartment of Medical Biology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Mehmet MemisDepartment of Molecular Biology, Gevher Nesibe Genom and Stem Cell Institute, Kayseri, Türkiye.
Elif Funda SenerDepartment of Molecular Biology, Gevher Nesibe Genom and Stem Cell Institute, Kayseri, Türkiye.
Serpil TaheriDepartment of Molecular Biology, Gevher Nesibe Genom and Stem Cell Institute, Kayseri, Türkiye.
Bulent OzpolatStephenson School of Biomedical Enginering, The University of Oklahoma, Norman OK, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Breast cancer is a heterogeneous disease comprising distinct molecular subtypes, including estrogen receptor-positive (ER+) breast cancer and triple-negative breast cancer (TNBC). MicroRNAs (miRNAs) regulate post-transcriptional gene expression and play important roles in cancer progression by functioning as oncogenic or tumor-suppressive molecules. Forkhead box M1 (FOXM1) is an oncogenic transcription factor that is frequently upregulated in aggressive breast cancers, particularly TNBC, and is associated with proliferation, invasion, metastasis, therapy resistance, and poor prognosis. Materials and Methods: Clinically relevant miRNAs associated with survival in patients with ER+ and ER- breast cancer were identified using publicly available datasets. The expression levels of miR-34a-5p, miR-873-5p, miR-193b-5p, miR-330-5p, miR-10b-5p, miR-155-5p, and miR-484 were evaluated in MDA-MB-231 TNBC cells and MCF-7 ER+ breast cancer cells following FOXM1 knockdown. Results: FOXM1 knockdown was associated with increased expression of several tumor-suppressive miRNAs, including miR-34a-5p, miR-873-5p, miR-193b-5p, miR-330-5p, miR-10b-5p, and miR-484, in MDA-MB-231 cells. In contrast, most of these miRNAs were not markedly altered in MCF-7 cells, except for miR-10b-5p, whose expression decreased following FOXM1 knockdown. miR-155-5p expression remained largely unchanged in both cell lines. Conclusion: Our findings demonstrate that FOXM1 knockdown was associated with differential expression of clinically relevant miRNAs in the two breast cancer cell models examined. These findings suggest that FOXM1-associated alterations in miRNA expression may contribute to the aggressive phenotype of TNBC and warrant further mechanistic investigation.

Indexed as

Breast cancerestrogen receptor-positive breast cancerFOXM1microRNAmiR-10b-5pmiR-193b-5pmiR-34a-5ptriple-negative breast cancer

Identifiers

PMID42871514
PMCPMC13659204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.